1,263 reports of this reaction
3.2% of all Brilinta reports
#5 most reported adverse reaction
OFF LABEL USE is the #5 most commonly reported adverse reaction for Brilinta, manufactured by Rising Pharma Holdings, Inc.. There are 1,263 FDA adverse event reports linking Brilinta to OFF LABEL USE. This represents approximately 3.2% of all 39,143 adverse event reports for this drug.
Patients taking Brilinta who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among Brilinta users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for Brilinta:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 1,263 FDA reports for Brilinta. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 3.2% of all adverse event reports for Brilinta, making it a notable side effect.
If you experience off label use while taking Brilinta, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.